Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases

Abstract

Nanoparticles represent a new generation of drug delivery systems that can be engineered to harness optimal target selectivity for specific cells and tissues and high drug loading capacity, allowing for improved pharmacokinetics and enhanced bioavailability of therapeutics. The spontaneous propensity of both organic and colloidal nanoparticles to be captured by the cells of the reticuloendothelial system encouraged their utilization as passive targeting systems that can be preferentially directed to innate immune cells, such as macrophages, dendritic cells and neutrophils. The natural affinity for phagocytic cells suggests the possible implementation of nanoparticles as an immunotherapeutic platform for inflammatory diseases and autoimmune disorders. Here we discuss the recent advances in the application of nanotechnology to induce antigen-specific tolerance in autoimmunity and the use of nanoparticles for anti-inflammatory therapies, including treatment of inflammatory bowel diseases, psoriasis and rheumatoid arthritis.

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

“…In a drug delivery framework, the nanoformulation is intended to enhance the drug protection and permeability, to extend the therapeutic agent half-life, to improve the drug solubility and/or increase its therapeutic index [62]. As already stressed above, different types of drugs, including both small molecules and biologics, can benefit from nanoscale DDSs in enhancing their therapeutic efficacy.…”

Recent advances in "smart" delivery systems for extended drug release in cancer therapy

“…Extended-release NPs are attractive therapeutic options for the long-term treatment of complex chronic diseases, such as cancer, owing to drug release over a prolonged period. 144,145 These characteristics of extended-release NPs can achieve improved patient compliance, better life-cycle management of drugs, and extended relief of symptoms, due to a reduction in fluctuating drug levels. 146 The clinical advantages of smart NPs are summarized in Figure 4.…”

Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases

“…[124,126,129] In addition, their high propensity toward phagocytosis by immune cells makes them ideal candidates for the exploration of cell-targeted therapies toward disease resolution. [130] In contrast to the necessity of biocompatibility and cellular uptake of biomaterials for drug delivery applications, sensors for the quantification of biomarkers from patient samples ex vivo are driven by the need for accurate measurement of analytes with low concentrations. The majority of biosensors are designed to meet two goals simultaneously.…”